A $93 billion plunge in Novo Nordisk A/S shares has provided the latest blow to Europe’s largest listed companies, which have spent another year struggling in vain to match the returns of Wall Street’s biggest stocks.
A $93 billion plunge in Novo Nordisk A/S shares has provided the latest blow to Europe’s largest listed companies, which have spent another year struggling in vain to match the returns of Wall Street’s biggest stocks.
